Article

Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation.

Institut de Recherche en Immunologie et Cancérologie, Département de Biochimie and Groupe de Recherche Universitaire sur le Médicament, Université de Montréal, Montréal, QC, Canada H3C 3J7.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 04/2012; 109(17):E1028-37. DOI: 10.1073/pnas.1112422109
Source: PubMed

ABSTRACT G protein-coupled receptors (GPCRs) have been shown to activate the mitogen-activated protein kinases, ERK1/2, through both G protein-dependent and -independent mechanisms. Here, we describe a G protein-independent mechanism that unravels an unanticipated role for β-arrestins. Stimulation of the V2 vasopressin receptor (V2R) in cultured cells or in vivo in rat kidney medullar collecting ducts led to the activation of ERK1/2 through the metalloproteinase-mediated shedding of a factor activating the insulin-like growth factor receptor (IGFR). This process was found to be both Src- and β-arrestin-dependent. Whereas Src was found to act upstream of the metalloproteinase activation and be required for the release of the IGFR-activating factor, β-arrestins were found to act downstream of the IGFR transactivation. Unexpectedly, the engagement of β-arrestins by the IGFR but not by the V2R was needed to promote the vasopressin-stimulated ERK1/2 activation, indicating that a pool of β-arrestins distinct from those β-arrestins recruited to the V2R acts downstream of the receptor tyrosine kinase to activate ERK1/2. Such a dual site of action for β-arrestins helps explain the pleiotropic actions of this scaffolding protein. Given the role that V2R-stimulated ERK1/2 plays in kidney cell proliferation, this transactivation mechanism may have important implications for renal pathophysiology. Still, the role of β-arrestins downstream of a transactivation event is not limited to the V2R, because we observed a similar involvement for an unrelated GPCR (the platelet-activating factor receptor), indicating that it may be a general mechanism shared among GPCRs.

Download full-text

Full-text

Available from: Maïthé Corbani, Jul 25, 2014
2 Followers
 · 
128 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: β-Arrestins 1 and 2 are ubiquitously expressed proteins that play a dual role in G protein-coupled receptor (GPCR) signaling. On the one hand, arrestins are central to the termination of G protein-mediated receptor signaling and subsequent clathrin-dependent internalization. On the other hand, these proteins act as molecular scaffolds for G protein-independent GPCR signaling. This review provides an overview of how these dual functions of arrestins contribute to the biological outcomes associated to the activation of different brain GPCR. It also explores recent evidence suggesting how the dual function of arrestins can lead to the development of more selective pharmacological approaches for the treatment of central nervous system disorders such as chronic pain, bipolar disorder, major depression, and schizophrenia. Development of such approaches may lead to new drugs having better clinical efficacy and lesser side effects.
    Progress in molecular biology and translational science 01/2013; 118:267-95. DOI:10.1016/B978-0-12-394440-5.00011-5 · 3.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To influence physiology and pathophysiology, G protein-coupled receptors (GPCRs) have evolved to appropriate additional signalling modalities, such as the activation of adjacent membrane receptors. The epidermal growth factor receptors (EGFRs) mediate important growth and remodelling actions of GPCRs, although the precise network of gene products and molecular cascades linking GPCRs to EGFRs (termed EGFR transactivation) remain incomplete. In this review, we present the current view of GPCR-EGFR transactivation, identifying the established models of receptor cross-talk. We consider the limitations in our current knowledge and propose that recent advances in molecular and cell biology technology, including functional genomics approaches, will allow a renewed concentration of our efforts on understanding the mechanism underlying EGFR transactivation. Using an unbiased approach to the identification of the molecules required for GPCR-mediated EGFR transactivation will provide a contemporary and more complete representation from which to extrapolate therapeutic control in diseases from cardiovascular remodelling to cancer. This article is protected by copyright. All rights reserved.
    FEBS Journal 09/2013; 280(21). DOI:10.1111/febs.12509 · 3.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The insulin-like growth factor type 1 receptor (IGF-1R) plays a key role in the development and progression of cancer; however, therapeutics targeting it have had disappointing results in the clinic. As a receptor tyrosine kinase (RTK), IGF-1R is traditionally described as an ON/OFF system, with ligand stabilizing the ON state and exclusive kinase-dependent signaling activation. Newly added to the traditional model, ubiquitin-mediated receptor downregulation and degradation was originally described as a response to ligand/receptor interaction and thus inseparable from kinase signaling activation. Yet, the classical model has proven over-simplified and insufficient to explain experimental evidence accumulated over the last decade, including kinase-independent signaling, unbalanced signaling, or dissociation between signaling and receptor downregulation. Based on the recent findings that IGF-1R "borrows" components of G-protein coupled receptor (GPCR) signaling, including β-arrestins and G-protein-related kinases, we discuss the emerging paradigm for the IGF-1R as a functional RTK/GPCR hybrid, which integrates the kinase signaling with the IGF-1R canonical GPCR characteristics. The contradictions to the classical IGF-1R signaling concept as well as the design of anti-IGF-1R therapeutics treatment are considered in the light of this paradigm shift and we advocate recognition of IGF-1R as a valid target for cancer treatment.
    Cellular and Molecular Life Sciences CMLS 11/2013; 71(13). DOI:10.1007/s00018-013-1514-y · 5.86 Impact Factor